Approval · Notice of Compliance 766 · 2002
PAXIL: Notice of Compliance 766
Issued April 19, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 766
- Date
- April 19, 2002
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: symptomatic treatment of posttraumatic stress disorder
- Therapeutic class
- Antidepressant-antiobsessional-antipanic-anxiolytic agent-social phobia (social anxiety disorder)-posttraumatic stress disorder therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PAXIL | Not yet assigned | — |
Medicinal ingredients
- PAROXETINE HYDROCHLORIDE 10 MG per TAB
- PAROXETINE HYDROCHLORIDE 20 MG per TAB
- PAROXETINE HYDROCHLORIDE 30 MG per TAB
- PAROXETINE HYDROCHLORIDE 50 MG per TAB